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Abstract
Background: Germline mutations are heritable and may cause health disadvantages in the next generation.
To investigate trans-generational mutations, we treated male gpt delta mice with N-ethyl-N-nitrosourea (ENU)
(85 mg/kg intraperitoneally, weekly on two occasions). The mice were mated with untreated female mice and
offspring were obtained. Whole exome sequencing analyses were performed to identify de novo mutations in
the offspring.
Results: At 20 weeks after the treatment, the gpt mutant frequencies in the sperm of ENU-treated mice were
21-fold higher than those in the untreated control. Liver DNA was extracted from six mice, including the
father, mother, and four offspring from each family of the ENU-treated or untreated mice. In total, 12 DNA
samples were subjected to whole exome sequencing analyses. We identified de novo mutations in the
offspring by comparing single nucleotide variations in the parents and offspring. In the ENU-treated group,
we detected 148 mutation candidates in four offspring and 123 (82 %) were confirmed as true mutations by
Sanger sequencing. In the control group, we detected 12 candidate mutations, of which, three (25 %) were
confirmed. The frequency of inherited mutations in the offspring from the ENU-treated family was 184 × 10−8
per base, which was 17-fold higher than that in the control family (11 × 10−8 per base). The de novo mutation
spectrum in the next generation exhibited characteristic ENU-induced somatic mutations, such as base
substitutions at A:T bp.
Conclusions: These results suggest that direct sequencing analyses can be a useful tool for investigating
inherited germline mutations and that the germ cells could be a good endpoint for evaluating germline
mutations, which are transmitted to offspring as inherited mutations.
Keywords: Exome sequencing, Germline mutation, Heritable mutation, Mutation spectrum, Transgenic rodent
gene mutation assay
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Background
Gene mutations induced in germ cells may cause herit-
able changes, which can have adverse health effects on
the next generation. Thus, analyses of germ cell muta-
tions and risk evaluations for trans-generational muta-
genesis induced by chemicals are important research
subjects in genotoxicology [1]. Many genotoxicity and
mutagenicity tests employ somatic cells to detect muta-
gens, which may have carcinogenic potential. Indeed,
about 50 mutagens have been analyzed as rodent germ
cell mutagens and about 40 of them were positive [2].
Mouse-specific locus tests and mouse heritable trans-
location tests have been used to detect trans-
generational mutations [3, 4]; however, these tests are
rarely performed anymore as they need considerably
large numbers (hundreds to thousands) of animals.
Some genotoxicity/mutagenicity tests are also applicable
to germ cells, e.g., transgenic rodent (TGR) gene muta-
tion assays are useful for detecting mutations in both
somatic and male germ cells [5]. Recent advances in
high-throughput sequencing techniques have extended
the use of direct sequencing to mutation analyses. Thus,
a combination of TGR mutation assay and next-
generation sequencing (NGS) could be a comprehensive
approach for analyzing heritable mutations. In this study,
we estimated the N-ethyl-N-nitrosourea (ENU)-induced
germline mutation frequency (MF) in gpt delta trans-
genic mice by whole exome sequencing using NGS.
ENU is a known germ cell mutagen, and it has been
used to generate mutant mice in large-scale chemical
mutagenesis projects [6–8]. We treated male mice with
ENU and mated them with untreated females at 10 weeks
after the treatment. Whole exome sequencing was per-
formed for the parents and offspring of the ENU-treated
and control families, and de novo germline mutations were
detected by comparing single nucleotide variants (SNVs)
in the parents and offspring. We also estimated the gpt
mutant frequency in sperm DNA from the ENU-treated
mice. Our results showed that the frequency of inherited
mutations was clearly higher in the ENU-treated group
than that in the control group. The mutation spectrum
determined by NGS indicated the presence of characteris-
tic ENU-induced mutations. Thus, NGS may be a power-
ful approach for analyzing chemically induced trans-
generational mutations, and germ cells could be a good
surrogate for trans-generational mutagenesis studies.
Methods
Treatment of animal
Male and female gpt delta mice (C57BL/6 J background)
[9, 10] were obtained from a breeding colony maintained
at the National Institute of Health Sciences. The animal
treatment employed in this study was approved by the
Animal Care and Utilization Committee of the institute.
The experimental design was based on a protocol for
mouse mutagenesis using ENU [11] and a previously re-
ported RIKEN ENU mutagenesis project [12], with some
modifications. Nine-week-old male mice were treated
with ENU (85 mg/kg body weight intraperitoneally,
weekly on two occasions) (Additional file 1: Figure S1).
The male mice were pre-mated with untreated female
mice at 6–7 weeks after the last treatment to check for a
period of infertility induced by ENU. Exposure to ENU
was confirmed by their temporal sterility. Ten weeks
after the last treatment, the male mice were mated with
untreated female mice and F1 offspring were obtained.
Control male mice were treated with phosphate/citrate
buffer as vehicle and mated with untreated females
without a pre-mating period. Five male mice were used
in each group. After the offspring were obtained, male
mice were sacrificed at 20 weeks after the last treat-
ment (30 week-old), and their tissues were then col-
lected and stored at −80 °C. The mated females and the
offspring were also sacrificed at 30–33 and 5 weeks old,
respectively.
Reporter gene mutation assay
Genomic DNA was extracted from the liver using a
RecoverEase DNA Isolation Kit (Agilent Technologies,
Santa Clara, CA). Sperm DNA was extracted as de-
scribed [13] with some modifications. In brief, the cauda
epididymis was chopped in 1 mL of phosphate-buffered
saline (pH 7.4), filtered, and pelleted by centrifugation.
The pellet was re-suspended in 1× saline sodium citrate
(SSC) and 0.15 % sodium dodecyl sulfate (SDS). The lys-
ate was centrifuged and the sperm pellet was suspended
in 1 mL of 0.2× SSC, 1 % SDS, 1 M 2-mercaptoethanol,
and 10 mM EDTA (pH 8.0), before digesting overnight
with 0.5 mg/mL proteinase K at 37 °C. DNA was iso-
lated by extracting four times in phenol/chloroform,
ethanol precipitation, and re-suspension in TE buffer
(pH 8.0). For the gpt gene mutation assay, lambda EG10
transgenes were rescued by in vitro packaging reactions
as phage particles using Transpack Packaging Extract
(Agilent Technologies). The gpt mutation assay was per-
formed as described previously [14]. In brief, the rescued
phages were used to infect Escherichia coli strain
YG6020, which expressed Cre recombinase to convert
the transgene into a plasmid. The infected cells were
mixed with molten soft agar and poured onto M9 agar
plates containing chloramphenicol (Cm) and 6-
thioguanine (6TG). The plates were incubated for 4 days
at 37 °C to select colonies that harbored the plasmid carry-
ing the mutated gpt gene. Infected cells were also poured
onto plates containing Cm without 6TG to determine the
number of rescued plasmids. The gpt mutant frequencies
were calculated by dividing the number of 6TG-resistant
colonies by the number of rescued plasmids. The gpt
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mutants obtained from the sperm of ENU-treated mice
were sequenced to determine the gpt mutations using an
ABI3730 sequencer (Applied Biosystems by Life Technolo-
gies, Carlsbad, CA) with a sequencing primer gptA2 (5′-
TCTCGCGCAACCTATTTTCCC-3′).
High-throughput DNA sequencing analysis
One ENU-treated family and one control family were
employed in the high-throughput sequencing analyses
(Fig. 1), where each family comprised six mice, i.e., par-
ents (male and female) and offspring (two males and
two females). Genomic DNA was extracted from the
liver using a Wako DNA Extractor WB Kit (Wako,
Osaka, Japan). Liver DNA samples from 12 mice were
subjected to NGS analyses by Beckman Coulter Genomics
(MA, USA). Genomic DNA was fragmented using the
Covaris DNA shearing system (Covaris, Inc., MA, USA).
The whole mouse exome (49.6 Mb) was captured using a
SureSelect Mouse All Exon Kit (Agilent Technologies)
and sequenced by a Hiseq2000 (Illumina, CA, USA) with
100-bp paired-ends. Sequenced reads were mapped onto
the reference sequence using ELAND (Illumina). The ref-
erence sequence was C57BL/6 J mouse genome: NCBI
Build 37, mm9 (http://www.ncbi.nlm.nih.gov/projects/
genome/assembly/grc/mouse/), and the SureSelect Mouse
All Exon Kit was designed using the same reference se-
quence. For each animal, the SNVs were called based on
comparisons with the reference sequence using Samtools.
Calculation of the frequency of inherited mutations in the
offspring of ENU-treated and control fathers
The SNVs were compared in the parents and offspring,
and de novo mutations were identified as follows. (1)
The SNVs transmitted from the parents were excluded.
(2) The SNVs found only in one offspring (not found in
the other 11 mice) were considered as unique mutations
and selected as candidate de novo mutations. (3) The
read depth, i.e., the number of sequencing reads that
covered one nucleotide position, had to exceed 40 in all
three mice, i.e., father, mother, and offspring (see the
Results). (4) The genotype quality (GQ) scores in NGS
had to exceed 20 (=99 % accuracy) in all three mice. The
frequency of inherited mutations was calculated as fol-
lows. The number of de novo mutations was divided by
the number of bases in the exome with the same cut-off
value, i.e., a read depth ≥ 40 and GQ score ≥ 20 in all
three mice. The NGS data were analyzed by Genaris
Omics Inc. (Kanagawa, Japan). Confirmation of the mu-
tation candidates by Sanger sequencing was performed
by TAKARA BIO Inc. (Shiga, Japan) using an ABI3730
sequencer (Applied Biosystems by Life Technologies)
with custom-designed PCR primers for each mutated
position in the genome of offspring.
Results
ENU treatment and gpt mutant frequency
The male mice were treated with ENU and a pre-mating
period was enforced to check their temporal infertility
due to ENU at weeks 6–7 after the last treatment. No
pregnancies occurred during the pre-mating period. At
week 10, the mice were mated with untreated females to
obtain offspring. In total, 24 F1 mice comprising 17 males
and 7 females were obtained from five mated pairs. Tissue
samples were collected from the paternal, maternal, and
F1 mice. Exposure to ENU was confirmed by the gpt mu-
tation assay (Fig. 2). The gpt mutant frequency in the liver
of ENU-treated mice (88.4 ± 25.4 × 10−6) was 37-fold
higher than that in the control mice (2.4 ± 1.5 × 10−6). In
the sperm of ENU-treated mice, the gpt mutant frequency
(44.4 ± 25.9 × 10−6) was 21-fold higher than that of the
control mice (2.1 ± 1.7 × 10−6). In the offspring of ENU-
treated fathers, the gpt mutant frequency in the liver
(3.0 ± 3.6 × 10−6) did not differ significantly from that of
the control fathers. One ENU-treated mouse (ID = 8: gpt
mutant frequency = 74.1 × 10−6) and one control mouse
(ID = 43: gpt mutant frequency = 1.2 × 10−6) were selected
randomly, and their families with the paired female and
offspring were used for the NGS analyses.
Frequency of inherited mutations in ENU-treated mice
Genomic DNA samples prepared from the livers of one
ENU-treated and one vehicle-treated family were subjected
Fig. 1 Mouse families used for analyses of whole exome sequencing. For each family, six mice comprising the parents (one male and one
female) and four offspring (two males and two females) were used for whole exome sequencing analyses. Each animal ID is presented
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to whole exome sequencing (Fig. 1). Initial read data com-
prising 12–20 gigabases (Gb) were obtained from each ani-
mal. The sequenced reads were mapped onto the reference
mouse genome sequence, where 54–66 % of the mapped
reads were mapped onto the exon region. Thus, over 5 Gb
of the sequenced data were mapped onto the 49.6-Mb
exon region (approximately 100-fold redundancy). For
70 % of the bases in the exome, the read depth exceeded
30. For each animal, SNVs and small Indels were detected
based on comparisons with the reference sequence.
The SNVs were compared in the parents and off-
spring, and de novo mutation candidates were scored in
the offspring (unique mutations only). The mutation
candidates were sorted by using the read depth as a cut-
off value. When a higher read depth was set, less muta-
tion candidates were sorted (Additional file 2: Table S1).
The ratio of the total number of mutation candidates in
the ENU-treated group relative to that of the candidates
in the control group was plotted as well as the read depth
(Fig. 3). The ratio increased with the read depth and
peaked when the read depth ≥ 40, at which it was > 12.
This was the most sensitive setting for detecting ENU-
induced de novo germline mutations under these experi-
mental conditions. Therefore, a read depth ≥ 40 in all
three mice (father, mother, and one offspring) was selected
as the cut-off value to calculate the frequency of inherited
mutations.
In the ENU group, 148 candidate mutations were de-
tected from four offsprings, whereas, 12 candidate muta-
tions were detected in the control group (Table 1). Most
mutation candidates (157/160) were single base substitu-
tions and three were small indels (two single base dele-
tions and one 2-base deletion) (Additional file 2: Table
S2). These candidate mutations were examined by
Sanger sequencing. In the ENU group, 83 % (123/148)
were confirmed as true mutations, whereas there were
many false calls in the control group and only 25 % (3/12)
were confirmed. All were detected as heterozygous point
mutations in the genomes of the offspring (Additional
file 2: Table S2). The MFs of each offspring were cal-
culated by dividing the number of mutations by the
number of the bases in exome, which was calculated





























Fig. 3 Relative ratio of the number of mutations detected in the offspring of ENU-treated and vehicle-treated fathers. Ratio of the total number
of de novo candidate mutations in four offspring from the ENU and control group. The thick arrow indicates the peak of the fold increase. When
read depth ≥40, the number of mutations in the ENU-treated group was 12-fold higher than that in the control group
Fig. 2 The gpt mutant frequencies in the liver and sperm of the
ENU-treated mice and their offspring. The gpt mutant frequencies
are presented with the standard deviations. ND: not determined.
Asterisks indicates significant differences vs the vehicle control
(p < 0.05, Kruskal–Wallis test)
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Table 1 Frequencies of inherited mutations in the offspring of ENU- or vehicle-treated father










99_1 Male 8 99 18,621,430 35 30 161.1
99_2 Male 8 99 13,301,379 42 34 255.6
99_4 Female 8 99 18,273,301 35 28 153.2
99_5 Female 8 99 18,590,333 36 31 166.8
Total 68,786,443 148 123 178.8 184.2 ± 47.9
Control
50_1 Male 43 50 6,874,190 2 2 29.1
50_2 Male 43 50 6,904,947 4 0 0.0
50_3 Female 43 50 6,743,247 2 1 14.8
50_4 Female 43 50 6,877,048 4 0 0.0















three mice (Additional file 3: Figure S2). The fre-
quency of inherited mutations in the ENU-treated mice
was 184 ± 48 × 10−8 bases, which was 17-fold higher than
that in the control group (11 ± 14 × 10−8 bases). In the
control group, fewer bases were sorted in the exome com-
pared with the ENU group because the NGS data quality
for animal ID 43, which was the father of the control fam-
ily, was lower compared with the quality for the other
mice analyzed. This low quality reduced the number of
mutation candidates that exceeded the cut-off value. In
this study, the false positive MF was about 30 × 10−8 bases
in both the ENU and control groups (Fig. 4).
Mutation spectra of inherited mutations in ENU-treated
mice
The spectrum of inherited mutations in the ENU-treated
mice is shown in Table 2. Among 123 confirmed muta-
tions, base substitutions at A:T bps were mainly observed
(90/123 = 73.2 %). A:T to G:C transitions occurred in
42.3 % of cases (52/123) and A:T to T:A transversions
were observed frequently (33/123 = 26.8 %). The control
group had only three confirmed mutations. No mutational
hotspots were observed in the ENU-induced mutations
(Additional file 2: Table S2). Non-synonymous mutations
in coding sequences accounted for 45 % of cases (55/123)
and 9 % were synonymous mutations (11/123) (Additional
file 2: Table S3). Intronic mutations comprised 19 % of
cases (23/123). In two cases, two mutations were identi-
fied at neighboring bases in the same animal, where A to
G at 27827556 and A to T at 27827557 in chromosome 5
of mouse ID 99_2 may be considered as AA to GT tan-
dem mutations, while T to C at 119834044 and A to T at
119834046 in chromosome 4 of mouse ID 99_5 may be
considered as TTA to CTT mutations.
The mutation spectrum of the gpt mutations in the
sperm of ENU-treated male mice is shown in Table 2,
which indicates that A:T to T:A transversions (34.7 %) and
G:C to A:T transitions (22.4 %) were mainly observed.
Discussion
De novo mutations in the offspring of the ENU-treated
father were identified by whole exome sequencing
followed by Sanger sequencing. Theoretically, the mini-
mum dataset required for analyzing de novo mutations is
a trio (parents and one offspring). However, using such a
small sample number may lead to many false positive
calls. It is expected that ENU induces point mutations
randomly in the genome at a frequency of 1/Mbp [12].
Thus, multiple identical mutations in different individuals
could be treated as sequencing errors rather than inde-
pendent mutations. To minimize the false mutation calls,
we counted unique mutations detected in one mouse
among the 12 mice used in this study as de novo candidate
mutations. After simply sorting the unique candidate mu-
tations by read depth ≥ 40 in all three mice (father, mother,
and one offspring), the number of candidate mutations in
the offspring of the ENU-treated father was over 12 times
higher than that in the control. Confirmation by Sanger
sequencing indicated that 83 % (123/148) of the ENU-
induced de novo candidate mutations were true mutations.
By contrast, only 25 % (3/12) were confirmed in the con-
trol group, and there were many false calls. In this study,
false positives mean that Sanger sequencing using the
same DNA sample could not confirm the potential NGS
mutations (Additional file 2: Table S2). Sanger sequencing
may not be able to confirm the mutations in some cases.
For example, mismatches or multiple targets of PCR
primers may cause failed PCR amplification. In another
example, if multiple copies of identical sequence are dis-
tributed in the genome, PCR may not preferentially amp-
lify the mutated locus and Sanger sequencing cannot
detect a signal of the mutated base. However, there is no
perfect explanation for discrepancy between NGS and
Sanger sequencing. SNVs detected by NGS may contain
some errors even if they have sufficient read depth.
Interestingly, the false positive MFs, i.e., approximately
30 × 10−8 bases, was similar in both the control and
ENU-treated groups (Fig. 4), which may indicate the
background level of false positives under this experimen-
tal condition. To reduce false positives, it may be neces-
sary to employ more animals, deeper sequencing, longer
target sequences, and to improve the SNV detection
methods. However, the false-negative rate was not deter-
mined in this study. The candidate mutations were
sorted to maximize the sensitivity of the method, i.e., ac-
cording to the ratio of a number of candidate mutations
Fig. 4 Frequencies of inherited mutations in the offspring of
ENU-treated or vehicle-treated fathers. Each bar represents average of
4 offspring with standard deviation. The confirmed mutation frequency
was 17-fold higher in the offspring of the ENU-treated father.
The frequency of false positives was about 30 × 10−8 bases
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NGS (this study) Genome-wide
screening1a
Transgenic reporter gene mutation assays Endogenous gene mutation assays
Target
sequences
Whole exome Whole exome 63 loci (197 Mb) gpt (this study) gpt2 lacZ3 lacZ4 lacI5 Hprt (cDNA)6 Hprt (exon 3)7
Target
tissues














G:C to A:T 1 33.3 21 17.1 32 22.4 11 22.4 17 28.3 6 24.0 7 35.0 13 29.5 4 12.9 2 3.9
A:T to G:C 1 33.3 52 42.3 53 37.1 8 16.3 12 20.0 1 4.0 2 10.0 10 22.7 7 22.6 14 27.5
Transversion
G:C to T:A 0 0.0 12 9.8 13 9.1 7 14.3 9 15.0 6 24.0 4 20.0 4 9.1 1 3.2 1 2.0
G:C to C:G 0 0.0 0 0.0 1 0.7 1 2.0 0 0.0 0 0.0 0 0.0 1 2.3 1 3.2 0 0.0
A:T to T:A 0 0.0 33 26.8 35 24.5 17 34.7 17 28.3 7 28.0 6 30.0 10 22.7 13 41.9 28 54.9
A:T to C:G 0 0.0 5 4.1 8 5.6 4 8.2 3 5.0 3 12.0 0 0.0 4 9.1 5 16.1 6 11.8
Deletion 1 33.3 0 0.0 1 0.7 1 2.0 2 3.3 1 4.0 1 5.0 1 2.3 0 0.0 0 0.0
Insertion 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 4.0 0 0.0 1 2.3 0 0.0 0 0.0
Total 3 100 123 100 143 100 49 100 60 100 25 100 20 100 44 100 31 100 51 100
1Male F1 mice by crossing C57BL/6 × DBA/2 or C3H/He [12]
2Male BDF1 gpt delta mice [10]
3Female CD2F1 MutaTM mice [17]
4Male CD2F1 MutaTM mice [18]
5Male B6C3F1 Big Blue® mice [19]
6C57BL/6 mice [30]
7Male B6C3F1 mice [19]















detected in the ENU and control groups. To avoid
underestimating the MF, we calculated the number of
nucleotides in the exome, which were sorted by the
same condition for mutation detection (read depth ≥40
in all three mice), and the MFs were estimated.
The frequency of confirmed inherited mutations in the
ENU-treated father was 184 ± 48 × 10−8 bases (Table 1).
The RIKEN ENU mutagenesis project estimated the
ENU-induced germline MF as 74.9 × 10−8 bases accord-
ing to a genome-wide screening of 197 Mbp of 7472 F1
genomes using temperature gradient capillary electro-
phoresis (TGCE) and Sanger sequencing [12]. Quwailid
et al. performed gene-based screening of 27.4 Mbp of
6000 F1 DNA using denaturing high-performance liquid
chromatography (HPLC) and determined a mutation
rate of 1 in 1 Mbp [15]. Concepcion et al. analyzed a
9.6 Mb sequence in 510 F1 mice and estimated a muta-
tion rate of 1.04 × 10−6 [16]. These ENU mutagenesis
studies were performed using a similar dosing design to
our study, i.e., two or three weekly intraperitoneal injec-
tions with 75–100 mg ENU/kg body weight. Therefore,
the ENU-induced MF range estimated by NGS in the
present study is comparable to those obtained using
other detection methods, such as TGCE, HPLC, and dir-
ect sequencing.
The mutation spectrum of the ENU-induced inherited
mutations is summarized in Table 2. The characteristic
ENU-induced mutations comprised base substitutions at
A:T bps, where A:T to G:C (42.3 %) and A:T to T:A
(26.8 %) were mainly observed in this study. The muta-
tion spectrum obtained from this NGS-based study ap-
pears to be considerably similar to the spectrum
produced in another genome-wide analysis using TCGE
[12]. However, the predominant type of gpt mutation in
the sperm of ENU-treated mice was A:T to T:A (34.7 %),
followed by G:C to A:T (22.4 %) and A:T to G:C
(16.3 %). Transgenic reporter gene assays have demon-
strated that the mutation spectra of ENU-induced som-
atic mutations include base substitutions at both A:T
and G:C bps [10, 17–19], where A:T to T:A and G:C to
A:T were the predominant mutations in the lacZ, lacI,
and gpt genes. This discrepancy may be explained by the
different targets used for mutation detection. The TGR
mutation assays used reporter genes for E. coli or
lambda phage integrated in the mouse chromosome,
which were not expressed and highly methylated [20,
21]. Whole exome sequencing mainly targets exons that
are expressed regions in the genome. ENU reacts dir-
ectly with DNA and generates a variety of DNA adducts
[22, 23], in which O4-ethylthymine, O2-ethylthymine,
and O6-ethylguanine are considered to be responsible
for causing A:T to G:C, A:T to T:A, and G:C to A:T mu-
tations [24–28]. Transcription-coupled repair may ex-
plain some of the differences in the mutation spectra
due to the effective repair of specific adducts in the ex-
ome sequence, e.g., nucleotide excision repair plays an
important role in the repair of guanine adducts [29].
The mutation spectra were also compared with those of
an endogenous reporter gene, Hprt, in splenic lympho-
cytes (Table 2). Interestingly, the mutation spectra of
Hprt showed that A:T base substitutions were most
common, as found in the NGS-driven mutation
spectrum [19, 30]. However, the major types were A:T
to T:A in the Hprt locus, but A:T to G:C according to
exome sequencing. These differences in the mutation
spectra are complex and they do not have simple expla-
nations, e.g., the Hprt and transgenic reporter gene as-
says involve phenotypic selection. Thus, the mutational
characteristics were biased by phenotypic changes in the
cells caused by the mutated gene products. In addition,
although the mutation spectra of Hprt were analyzed
using cDNA and exon 3, whole exome sequencing in-
cludes > 20 % out-of-exon sequences, such as intronic,
intergenic, and non-coding regions (Additional file 2:
Table S3). The sequence contexts also differ among the
genetic regions and organisms. Transgenic reporter
genes are bacterial genes and their codon usage differs
from that in the mouse. Thus, many factors could have
contributed to the differences in the mutation spectra.
In principle, genotypic selection might reflect in vivo
mutagenesis better than phenotypic selection because
there is no selection bias. However, it should be noted
that NGS also has technical biases in terms of sequen-
cing and mutation detection, such as a preference for
point mutations rather than larger indels.
The background control MF (11 ± 14 × 10−8 bases) and
mutation spectrum are difficult to discuss because of the
high standard deviation and the fact only three mutants
were confirmed. The germline mutation rate in humans is
considered to be about 1 × 10−8 per base per generation
[31–35]. The control germline and somatic MFs in mice
were also estimated as 1 × 10−8 per base or less [36, 37]. In
the whole exome sequencing, we used a 49.6 Mb target
sequence for each mouse. According to the sorting
condition employed in this study, i.e., read depth ≥ 40
in all three mice, the passed nucleotide sequences in the
exome comprised 13.6–13.9 % in the control group and
26.8 − 37.5 % in the ENU group (Additional file 3:
Figure S2). Therefore, the control MF of each animal
could have been zero because no mutations were de-
tected. Thus, more control mice and a deeper read depth
may be needed to analyze the background MF. Pooling
the background data obtained from the exome sequencing
of untreated control mice could also be useful for estimat-
ing the background MF and standard deviation in labora-
tory mice.
The gpt mutant frequency in the sperm of ENU-
treated father (44.4 ± 25.9 × 10−6) was 21 times higher
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than that in the control (2.1 ± 1.7 × 10−6). However,
the gpt mutant frequency in the liver of the ENU-
treated father’s offspring was the same as the background
level (3.0 ± 3.6 × 10−6). If ENU-induced germline gpt mu-
tations are transmitted to offspring, then a very high gpt
mutant frequency could be observed in the F1 mice. It has
been reported that there are approximately 40 copies of
each transgene per haploid in gpt delta mice [38]. If
one copy contains the inherited gpt mutation, then
the expected mutant frequency in the F1 mice would
be 1/80 = 12.5 × 10−3, which is 1000 times higher than
the control level. Based on the 24 F1 mice obtained
in this study, we screened 24 × 40 = 960 paternal gpt
loci. However, we did not observe clonal mutant mice.
The gpt mutant frequency in the sperm from the ENU-
treated mice was 44.4 × 10−6, and thus we would require
500 offspring to search for 20000 loci to detect germline
mutations at a frequency of 50 × 10−6. In fact, Barnett et
al. treated male Big BlueR mice with 300 mg ENU/kg body
weight and searched for transmitted mutations in 280 off-
spring, thereby finding four mice with clonal lacI muta-
tions in their whole bodies [39]. In contrast, whole exome
sequencing could search approximately 50-Mb regions in
each offspring. This suggested that high-throughput DNA
sequencing analyses could have higher sensitivity to detect
inherited mutations using smaller number of animals.
We compare the germline mutagenesis rates measured
by NGS and the gpt assay in Table 3. The frequency of
inherited mutations detected by NGS cannot be com-
pared directly with the gpt mutant frequency in sperm,
which is based on bacteria-mediated phenotypic selec-
tion using a reporter gene, but the increases in the
ENU-induced MFs were comparable in both the NGS
and gpt assay. This suggests that germ cells from the
ENU-treated father could be a good endpoint for evalu-
ating germline mutations, which are origins of inherited
mutations. It would be interesting to compare the
mutational characteristics of germ cell mutations and inher-
ited mutations, but the differences in the mutation spectra
obtained by the two methods may reflect different end-
points, e.g., whether the target sequence is expressed or
not. It should be noted that the control MF in this whole
exome-based study was higher than expected and it had a
high standard deviation, and the problem of false positives
still needs to be solved. Additional NGS data based on ana-
lyses of more families will help to obtain a more accurate
estimation of the MF. In particular, more control mice
should be analyzed to estimate the background MF. By
using a genetically-closed colony of laboratory animals, the
sequence data could be pooled from independent experi-
ments. If the sequencing cost decreases, whole genome se-
quencing will also be a better solution than whole exome
sequencing. In addition, genome-wide instability including
copy number and structural variations could also be import-
ant targets, as well as point mutations. The detection of de
novo mutations by NGS does not need specific transgenic
animals with reporter genes and it can be applied to any or-
ganism. Thus, this could be a powerful tool for investigating
inherited mutations and evaluating the mutagenic effects of
chemicals in the next generation in human populations.
Conclusions
In this study, we analyzed ENU-induced trans-generational
mutations by NGS with Sanger sequencing. ENU-treated
and control families of gpt delta mice were subjected to
whole exome sequencing analyses and we detected de novo
mutations in the offspring. The frequency of inherited mu-
tations in the offspring of the ENU-treated family was 17
times higher than that in the control family, and it was
comparable to the gpt mutant frequency in the sperm of
the ENU-treated mice. The ENU-induced inherited muta-
tion spectrum determined by NGS identified characteristic
base substitutions, such as A:T to G:C and A:T to T:A.
These results suggest that direct sequencing analyses using
Table 3 Summary of the germlime mutagenicity estimated by NGS and TGR mutation assay
NGS study TGR mutation assay
(Confirmed by Sanger seq.)
Background MF 11 ± 14 × 10−8/basea 2.1 ± 1.7 × 10−6/reporter geneb
ENU-induced MF 184 ± 48 × 10−8/basea 44.4 ± 25.9 × 10−6/reporter geneb
(Fold increase) (17-fold) (21-fold)
Target sequence Whole exome Neutral transgene
(49.6 Mb) (gpt: 456 bps)
Method of detection Direct sequencing Bacteria-mediated phenotypic selection
Source of DNA Liver of offspring Sperm of treated father
(Inherited mutation) (Germ cell mutation)
aIndependent mutation frequency. Unit = 1. (Each unit contains father, mother and 4 F1s.)
bgpt mutant frequency. N = 5
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NGS could be a powerful tool for investigating inherited
germline mutations and for evaluating the genotoxic effects
of mutagens in the next generation. In addition, germ cells
could also be a good endpoint for evaluating germline
mutations.
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